This is a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
The study aimed to enroll ninety-four (94) patients/care partners. The time period for enrollment was dependent on the uptake of KESIMPTA in the real-world.
Data collected for the study was obtained directly from the patient/care partner within the web-based database: De-identified data was stored on a secure server and transferred for analysis. Responses from the patient and care partner surveys were pooled for analysis of study endpoints.
Adult aged eighteen (18) years of age or over at the time of the survey Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen MS diagnosis based on 2017 McDonald criteria
Care Partner Inclusion Criteria:
Adult aged eighteen (18) years of age or over Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf
Patients with MS Exclusion Criteria:
Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial Active Hepatitis B virus (HBV) Cognitive impairment that would impact their ability to participate in a survey study
